Advocate (10 - 25 kg)
ATC code
Species
Dogs.
Indications
For dogs suffering from, or at risk from, mixed parasitic infections. The veterinary medicinal product is only indicated when use against fleas and one or more of the other target parasites is indicated at the same time.
• the treatment and prevention of flea infestation (Ctenocephalides felis),
• the treatment of biting lice (Trichodectes canis),
• the treatment of ear mite infestation (Otodectes cynotis), sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis),
• the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis),
• the treatment of circulating microfilariae (Dirofilaria immitis),
• the treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens),
• the prevention of cutaneous dirofilariosis (L3 larvae of Dirofilaria repens),
• the reduction of circulating microfilariae (Dirofilaria repens),
• the prevention of angiostrongylosis (L4 larvae and immature adults of Angiostrongylus vasorum),
• the treatment of Angiostrongylus vasorum and Crenosoma vulpis,
• the prevention of spirocercosis (Spirocerca lupi),
• the treatment of Eucoleus (syn. Capillaria) boehmi (adults),
• the treatment of the eye worm Thelazia callipaeda (adults),
• the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis).
The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Dose to be administered and administration route
To ensure a correct dosage, body weight should be determined as accurately as possible.
Dosage schedule:
The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight of the veterinary medicinal product.
For treatment or prevention of infestations with the parasites indicated for use of this veterinary medicinal product, the need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal’s lifestyle.
Weight of dog [kg] |
Pipette size to be used |
Volume [ml] |
Imidacloprid [mg/kg bw] |
Moxidectin [mg/kg bw] |
≤ 4 kg |
Advocate for small dogs |
0.4 |
minimum of 10 |
minimum of 2.5 |
> 4–10 kg |
Advocate for medium dogs |
1.0 |
10–25 |
2.5–6.25 |
> 10–25 kg |
Advocate for large dogs |
2.5 |
10–25 |
2.5–6.25 |
> 25–40 kg |
Advocate for extra-large dogs |
4.0 |
10–16 |
2.5–4 |
> 40 kg |
the appropriate combination of pipettes |
Flea treatment and prevention (Ctenocephalides felis)
One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine the veterinary medicinal product treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The veterinary medicinal product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.
Treatment of biting lice (Trichodectes canis)
A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
Treatment of ear mite infestation (Otodectes cynotis)
A single dose of the veterinary medicinal product should be administered. Loose debris should be gently removed from the external ear canal at each treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis)
A single dose should be administered twice 4 weeks apart.
Treatment of demodicosis (caused by Demodex canis)
The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against Demodex canis and leads to a marked improvement of clinical signs particularly in mild to moderate cases.
Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, the veterinary medicinal product can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.
As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.
Prevention of heartworm disease (D. immitis)
Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with the veterinary medicinal product, the advice provided in section 3.5 should be considered.
For prevention of heartworm disease, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit D. immitis larvae) are present. The veterinary medicinal product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with the veterinary medicinal product must be given within 1 month of the last dose of the former medication.
In non-endemic areas there should be no risk of dogs having heartworm. Therefore, they can be treated without special precautions.
Prevention of cutaneous dirofilariosis (skinworm) (D. repens)
For prevention of cutaneous dirofilariosis, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit D. repens larvae) are present. The veterinary medicinal product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month.
Treatment of microfilariae (D. immitis)
The veterinary medicinal product should be administered monthly for two consecutive months.
Treatment of cutaneous dirofilariosis (skin worm) (adult stages of Dirofilaria repens)
The veterinary medicinal product should be administered monthly for six consecutive months.
Reduction of microfilariae (skin worm) (D. repens)
The veterinary medicinal product should be administered monthly for four consecutive months.
Treatment and prevention of Angiostrongylus vasorum
A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
In endemic areas regular monthly applications will prevent angiostrongylosis and patent infection with Angiostrongylus vasorum.
Treatment of Crenosoma vulpis
A single dose should be administered.
Prevention of spirocercosis (Spirocerca lupi)
The veterinary medicinal product should be administered monthly.
Treatment of Eucoleus (syn. Capillaria) boehmi (adults)
The veterinary medicinal product should be administered monthly for two consecutive months. It is advisable to prevent auto-coprophagia between the two treatments in order to prevent possible reinfection.
Treatment of the eye worm Thelazia callipaeda (adults)
A single dose of the veterinary medicinal product should be administered.
Roundworm, hookworm and whipworm treatment (Toxocara canis, Ancylostoma caninum, Uncinaria stenocephala, Toxascaris leonina and Trichuris vulpis)
In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas non-endemic for heartworm, the veterinary medicinal product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.
Studies have shown that monthly treatment of dogs will prevent infections caused by Uncinaria stenocephala.
Method of administration
External use.
Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette, as shown.
For dogs up to 25 kg:
With the dog in a standing position, part the coat between the shoulder blades until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.
For dogs of more than 25 kg:
For easy application the dog should be standing. The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail. At each spot, part the coat until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin. Do not apply an excessive amount of solution at any one spot, as that could cause some of the veterinary medicinal product to run down the animal’s side.
Adverse reactions
Dogs:
Common (1 to 10 animals / 100 animals treated): |
Diarrhoea1, Vomiting1 Cough1, Dyspnoea1, Tachypnoea1 Inappetence1, Lethargy1 |
Rare (1 to 10 animals / 10,000 animals treated): |
Vomiting |
Very rare (< 1 animal / 10,000 animals treated, including isolated reports): |
Application site greasy fur2, Application site hair loss2, Application site itching2, Application site reddening2 Behavioural disorder (e.g. agitation)3 Hypersalivation4 Neurological signs (e.g. ataxia, muscle tremor)5 Pruritus Inappetence3, Lethargy3 |
1 These signs are common in heartworm positive dogs with microfilaraemia, and there is a risk of gastrointestinal signs and severe respiratory signs that may require prompt veterinary treatment.
2 These signs disappear without further treatment.
3 Transiently noted and related to sensation at application site.
4 This is not a sign of intoxication and disappears within minutes without treatment. Correct application will minimise licking of the application site.
5 Most neurological signs occur transiently.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
PRICE | Only for registered vets. Create a free profile to access all features.. Login |
---|---|
Art. Nr. | 04895/5002 |
EAN | 4007221044390 |